Cargando…
Pharmacoeconomic Analysis of Clopidogrel in Secondary Prevention of Coronary Artery Disease
BACKGROUND: When used as an alternative to or in addition to aspirin, clopidogrel has been demonstrated by some but not all randomized controlled trials to be effective in secondary prevention of cardiovascular (CV) events in patients with (1) coronary artery disease (CAD), (2) acute coronary syndro...
Autor principal: | Cheng, Judy W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438004/ https://www.ncbi.nlm.nih.gov/pubmed/17506599 http://dx.doi.org/10.18553/jmcp.2007.13.4.326 |
Ejemplares similares
-
Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting
por: Chang, Hyoung Woo, et al.
Publicado: (2019) -
Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis
por: Liu, Di, et al.
Publicado: (2023) -
Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease
por: Terpening, Chris
Publicado: (2010) -
Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
por: Algra, Ale, et al.
Publicado: (2000) -
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
por: Sharma, Rakesh K, et al.
Publicado: (2009)